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ABSTRACT
Coronavirus disease 2019 (COVID-19) is a highly infectious disease caused by the severe acute
respiratory syndrome coronavirus 2 virus (SARS-CoV-2). While children appear to experience less
severe disease than adults, those with underlying conditions such as kidney disease may be more
susceptible to infection. Limited data are present for children with kidney disease, and there are
limited prior reports of pediatric hemodialysis patients with COVID-19. This report describes the
mild clinical disease course of COVID-19 in two pediatric patients with chronic kidney disease, one
on hemodialysis and both on chronic immunosuppression. We review treatment in these patients,
as well as our measures to reduce transmission among our hemodialysis patients and staff.
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INTRODUCTION
Coronavirus disease 2019 (COVID-19), the disease caused
by severe acute respiratory syndrome coronavirus 2 virus
(SARS-CoV-2), has resulted in a global pandemic.1 The out-
break began in Wuhan, China, and spread rapidly across
the world, resulting in a global health emergency.1 Although
the majority of cases of COVID-19 are mild, a subset of
patients develops critical illness.2 Children appear to be less
susceptible to severe disease than adults with death reported
in <1%.3 However, disease course in children with com-
orbidities has not been well described. Chronic kidney dis-
ease (CKD), including end-stage renal disease (ESRD)
impairs immune function. Reports from China and Italy
indicate that adults with kidney disease may be at higher
risk of severe disease, with case fatality rates of between
10% and 30% reported.4 Paradoxically, the limited experi-
ence with patients with ESRD on hemodialysis suggests that
these patients may have a more mild course. Small studies
report COVID-19 death rates in adult patients with ESRD
on chronic dialysis ranging from <5% to 16%.1,4,5 This con-
tradictory epidemiologic data, along with the typically mild
course of COVID-19 in pediatric patients, has led to uncer-
tainty regarding the expected course and severity of SARS-
CoV-2 in pediatric patients with kidney disease on dialysis
and/or chronic immunosuppression.
This report describes the clinical characteristics of
SARS-CoV-2 infection in two pediatric patients with
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kidney disease on chronic immunosuppression, one of
whom has ESRD, managed with chronic in-center hemo-
dialysis. We review the clinical presentation and treat-
ment of these patients, as well as measures undertaken to
reduce transmission to other hemodialysis patients and
staff. This report does not require ethical approval per
the Institutional Review Board at our institution, and
informed consent was obtained from each patient
reported in this article for publication of the information
that appears within this case report.
CASE REPORTS
Patient 1
A 13-year-old, African American male presented to the
Emergency Department (ED) with complaints of fever,
fatigue, headache, and poor appetite. His past medical his-
tory included ESRD secondary to Henoch-Schonlein Pur-
pura, managed with thrice-weekly hemodialysis. Chronic
medications to control ongoing symptoms of his Henoch-
Schonlein Purpura included colchicine (almost 2 years of
treatment) and mycophenolate mofetil (approximately
6 months of treatment). He had no travel history over the
preceding 28 days and no sick contacts. He had no
rhinorrhea, conjunctivitis, shortness of breath, cough, nau-
sea, vomiting, nor diarrhea. He was afebrile at presentation,
with an oxygen saturation of 98% and a respiratory rate of
16 breaths per minute. He was mildly tachycardic with a
heart rate of 114 bpm and hypertensive with a blood pres-
sure of 143/86 mmHg. Physical examination was normal
with clear breath sounds. Laboratory testing was
unremarkable, and influenza swab was negative (Table 1).
He was discharged home to follow-up for hemodialysis per
routine.
The next day, the patient arrived for in-center hemodi-
alysis and was placed in an isolation room. He reported
ongoing fatigue, poor appetite, and headache. Given his
symptoms, he wore a surgical mask throughout
hemodialysis, and hemodialysis providers wore surgical
masks, gowns, gloves, and goggles. He became febrile to
38.4C during his hemodialysis session and was given
vancomycin and cefepime (until blood culture returned
negative). Additional labs were obtained including a
nasopharyngeal swab for SARS-CoV-2 by polymerase
chain reaction (PCR) using the Roche Cobas SARS-
COV-2 system for nucleic acid amplification, with RNA
extraction by the Roche automatic 6800 system. Follow-
ing an uneventful hemodialysis session, the patient was
discharged home to self-quarantine. The SARS-CoV-2
test returned positive the next day, and the patient was
diagnosed with COVID-19. Subsequently, he had sero-
conversion on a SARS-CoV-2 enzyme-linked immuno-
sorbent assays (ELISAs) (#KA5826, Abnova) with
confirmatory ELISAs performed at Mount Sinai Medical
Center using standard methodology previously reported.6
The threshold for a positive ELISA result was 0.14, a
value greater than the mean plus three times the standard
deviation of negative control, consistent with standard
methodology and with serum values of PCR-confirmed
positive control patients. Patients were considered to
have seroconverted if positive for IgM or IgG. The ELISA
sensitivity and specificity were not provided by the
manufacturer.6
On the day following his hemodialysis session, he
continued to feel tired, but no worse. His mother also
reported dry cough and subjective shortness of breath.
His mycophenolate mofetil was held for 1 week, and he
was prescribed hydroxychloroquine (300 mg orally twice
a day for 1 day, then 150 mg orally twice daily for 8 days)
per the institutional COVID-19 treatment protocol in
place at that time, which restricted hydroxychloroquine
use based on a risk- and illness severity-stratified classifi-
cation scheme.
The patient returned for scheduled hemodialysis
2 days later. He was afebrile with improved appetite and
energy level. He did not develop any additional symp-
toms. Repeat labs were performed (Table 1). He had a
chest X-ray obtained, which was normal (Figure 1).
Table 1 Laboratory results for patient 1
Laboratory test 2 Weeks prior to presentation At presentation 1 day following 3 days after
WBC 7.5 k/cumm 6.4 k/cumm 5.4 k/cumm 3.9 k/cumm
Hgb 10.6 gm/dL (L) 11.7 gm/dL (L) 10.9 gm/dL (L) 11.1 gm/dL (L)
Plts 309 k/cumm 124 k/cumm (L) 216 k/cumm 185 k/cumm
Abs Neut 4.5 k/cumm 4.5 k/cumm 3.1 k/cumm 1.3 k/cumm (L)
Abs Lymph 1.0 k/cumm 1.0 k/cumm 1.5 k/cumm 2.1 k/cumm
ESR — — 19 mm/h (H) 25 mm/h (H)
CRP — — <0.5 mg/dL <0.5 mg/dL
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Family reported compliance with hydroxychloroquine
and no side effects. The patient’s hemodialysis schedule
was altered so patient would dialyze in unit on days
without other patients present. Consistent staff members
were identified to provide care in order to limit potential
exposures. He remained asymptomatic thereafter. Despite
rapid clinical recovery, follow-up nasopharyngeal swab
remained positive for 21 days after first fever indicating
prolonged viral shedding, with first of two negative
swabs obtained 28 days after the initial fever.
Patient 2
An 18-year-old Hispanic male with membranoproliferative
glomerulonephritis (MPGN) type 1 presented for a sched-
uled outpatient eculizumab infusion, and incidentally
reported sudden onset anosmia. His past medical history
included CKD stage I due to MPGN. Chronic medications
for MPGN and CKD included prednisone, losartan, and
weekly eculizumab infusions (900 mg weekly due to
heavy proteinuria to target appropriate CH50 and
eculizumab trough levels). On further inquiry, he reported
complete anosmia and ageusia which had developed
abruptly 1 week prior to presentation. A nasopharyngeal
swab for SARS-CoV-2 was obtained and returned positive
the next day, and the patient was diagnosed with COVID-
19. Additionally, he had seroconversion on SARS-CoV-2
enzyme-linked immunosorbent assays (ELISAs) and
confirmatory ELISA.6 He reported no other symptoms
including no fever, sore throat, coughing, shortness of
breath, vomiting, nor diarrhea. His mother and father,
however, had experienced abrupt onset of fever, cough,
decreased appetite, fatigue, and night sweats beginning
2 to 3 weeks prior to onset of the patient’s anosmia. He
received no additional treatment, and required no alter-
ations in his chronic immunosuppression with all
eculizumab doses administered per usual schedule given
mild symptoms. All symptoms resolved on day 10 of
illness.
DISCUSSION
In this report, we describe the clinical course of two
pediatric patients with kidney disease and chronic immu-
nosuppression who developed COVID-19. To our
knowledge, this includes one of the first reported cases
of COVID-19 in a pediatric hemodialysis patient. The
clinical presentation of these patients was more mild than
that which has been described in adult patients with kid-
ney disease that have been reported to date. Although
neither patient had cough, sore throat, nasal congestion,
or dyspnea, each had at least one typical symptom of
COVID-19 (fever and anosmia).
Children with COVID-19 appear to have milder disease
than that seen in adults.7 While children are often asymp-
tomatic, fever—as was seen in our first patient—is a com-
mon presenting sign.7,8 Patients with ESRD have
abnormal B- and T-cell function, blunted immune
response, and increased infection risk.5,9 This impaired
immune response, however, may also be responsible for
mild disease severity.10 We note that patient 1 had an ini-
tial relative decrease in his white blood cell count at the
time of acute SARS-CoV-2 infection, followed by a slow
and more sustained increase in absolute lymphocyte
count following infection. Lymphopenia is common in
COVID-19 and may be a factor associated with severity of
disease and mortality.11 Both patients’ immune responses
may have been further impaired due to immunosuppres-
sive medications (colchicine and mycophenolate mofetil in
the first, eculuzimab and chronic prednisone in the sec-
ond). This mild course is similar to other reports of chil-
dren on chronic immunosuppressive therapy including
immunomodulators and biologic therapies.12,13 We specu-
late that immunosuppression may be at least in part
responsible for the mild disease course observed in these
patients; however, we acknowledge that this may also sim-
ply reflect the overall more mild course generally seen in
children. We also note the prolonged viral shedding in
patient 1 (21 days), which has been reported in other case
Figure 1 Normal chest X-ray obtained 4 days after patient
1’s presentation.
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series and others have speculated may be due to
immunosuppression.14
Hemodialysis patients represent a high-risk group for
COVID-19 for several reasons. First, they are unable to
strictly quarantine at home due to need for hemodialysis
treatment several times weekly. Additionally, in the
United States, pediatric hemodialysis patients often reside
far from their dialysis centers in communities with rela-
tively lower population density than that of their “home”
dialysis unit. This imposes a medical need for signifi-
cantly more than average mobility as they travel to and
from areas with differing COVID-19 disease prevalence,
even during stay-at-home orders. Due to financial and
social constraints related to the costs of their medical
care, it is also common for these patients to require either
subsidized (i.e., “Medicaid transportation”) or shared
transportation to their dialysis treatments. Thus, as they
travel to and from dialysis, they may inadvertently
become a source of respiratory virus spread to their fam-
ily or local community. Additionally, the design of hemo-
dialysis units (with several patients, family members, and
care providers in a confined space) increases the risk of
ongoing transmission within the health care environs.15
Finally, dialysis units have limited isolation rooms avail-
able, and nursing is often tasked with taking care of mul-
tiple patients at a time. Due to these factors, the infection
rate of hemodialysis patients in Wuhan was higher than
that of the general population.5 It is essential to take pre-
cautions to limit exposure to other hemodialysis patients
and healthcare staff. To decrease the risk of transmission,
all hemodialysis patients and staff wore surgical masks at
all times when in the dialysis unit once community-based
transmission of SARS-CoV-2 was identified, and nones-
sential personnel entry into the hemodialysis unit was
sharply limited. Our first patient was also placed in an
isolation room as soon as symptoms were reported,
according to unit protocols established based on contem-
poraneous CDC recommendations. Finally, his hemodial-
ysis schedule was changed to avoid contact with other
patients and staff as much as possible. During the ongo-
ing COVID-19 pandemic additional measures to reduce
risk of transmission of COVID-19 within dialysis units
have been implemented. These CDC recommended mea-
sures include intensive cleaning procedures, universal
PPE, and quarantining/isolating suspected cases.16 Other
centers have reported implementation of similar precau-
tions with low incidence of COVID-19 cases thereafter.17
The pandemic has resulted in deaths in COVID-19
infected hemodialysis patients; however, a percentage of
these deaths have been attributed to reductions in hemo-
dialysis therapy.6 Therefore, it is imperative that hemodi-
alysis patients with COVID-19 continue to receive
appropriate hemodialysis therapy to prevent these
complications.18
In conclusion, we report the first two case of
COVID-19 in pediatric patients with kidney disease. Their
mild disease, which may be influenced by young age,
chronic immunosuppression, or immune dysregulation
due to kidney disease also provides additional credence to
studying new treatments targeting the immune system in
COVID-19 patients. We also describe an effective method
of limiting ongoing SARS-CoV-2 transmission in a busy,
pediatric dialysis center.
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